Product Search for VE Cadherin: Novus Biologicals

AF1002

VE-Cadherin Antibody [Unconjugated]

(3 Reviews)

100 μg

AF1002

HAF017). A specific band was detected for VE‑Cadherin at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox">

Western blot shows lysates of mouse lung tissue and bEnd.3 mouse endothelioma cell line. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Mouse VE‑Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1002) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # <a class=

HAF017). A specific band was detected for VE‑Cadherin at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysates of mouse lung tissue and bEnd.3 mouse endothelioma cell line. PVDF membrane was probed with 0.2 µg/mL of Goat Anti-Mouse VE‑Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1002) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for VE‑Cadherin at approximately 120 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

VE-Cadherin was detected in immersion fixed paraffin-embedded sections of mouse heart using Goat Anti-Mouse VE-Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1002) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (Catalog # <a class=

VC004). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to cell membranes. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

Simple Western lane view shows lysates of mouse lung tissue, loaded at 0.2 mg/mL. Specific bands were detected for VE‑Cadherin at approximately 118, 146 kDa (as indicated) using 10 µg/mL of Goat Anti-Mouse VE‑Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1002) . This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

Chronic intermittent hypoxia modifies the BM vascular structure. a’–e’ Representative images of femur bone marrow stained with vWF, CD105, VE-cadherin, SMA, and CD11b counterstained with hematoxylin. a”, c”, d” BM from CIH exposed rats (n = 6) has more VE-cadherin+ vessels and SMA coverage but less vWF+ sinusoids (400×, Leica DM2500). e’, e” Representative images of CD11b immunohistochemistry in femur BM show an increase in BM monocyte count in CIH exposed animals. (400×, Leica DM2500) a’, a”’, b’, b” No changes in the total number of vessels or in megakaryocyte count were observed, as accounted by CD105 and vWF staining, respectively. Results are represented as the mean ± SD of bone marrow sections from six male Wistar rats (*p < 0.05; **p < 0.01). f Representative images of femur bone marrow fluorescently immunostained for VE-cadherin show an increase in total VE-cadherin vessels and in VE-cadherin vessel coverage. Scale bar, 50 μm (insets magnified 2.5×). Images were acquired with a Zeiss LSM 510 META microscope Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26856724), licensed under a CC-BY license. Not internally tested by R&D Systems.

AF1002) at 3ug/mL with 1 hour incubation at room temperature followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to cardiac myocytes. " class="big_lightbox">

Formalin-fixed paraffin-embedded tissue sections of mouse heart were probed for VE-Cadherin mRNA (ACD RNAScope Probe, catalog #312538; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using goat anti-mouse VE-Cadherin polyclonal antibody (R&D Systems catalog # <a class=

AF1002) at 3ug/mL with 1 hour incubation at room temperature followed by incubation with anti-goat IgG VisUCyte HRP Polymer Antibody (Catalog # VC004) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to cardiac myocytes. " class="big_thumb" />

Warfarin pretreatment enhances tumor Ad5ROBO4 vector expression.A. Multiorgan immunoblot of vehicle (left lanes) or warfarin (right lanes) pretreated Rag2−/− mice injected with 1.0×1011 vp of Ad5ROBO4. B. Densitometry of A revealed that vehicle pretreatment was associated with robust liver, detectable splenic, and trace to undetectable expression in all other sampled organs. Warfarin pretreatment produced a 2.5-fold increased splenic and a 3-fold decreased liver expression while all other organs still evidenced trace to undetectable expression. C. Immunoblot and densitometry of liver and tumor EGFP, VE-cadherin, and beta -tubulin expression in vehicle (left lanes) or warfarin (right lanes) from the same pretreated, Ad5ROBO4-injected mice as in A and B. EGFP densitometry normalized to VE-cadherin, revealed a 4.7-fold decrease in liver and 2-fold increase in increase KO and SC tumor expression produced by warfarin pretreatment. A–C: representative immunoblots from n = 2 mice from 2 independent experiments. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24376772), licensed under a CC-BY license. Not internally tested by R&D Systems.

Semiquantitative immunoblotting reveals differential Ad5ROBO4 reporter expression in tumor compared to liver.A. Immunoblot of EGFP, VE-cadherin, and beta -tubulin loading controls in tissue protein extracts from hCAR:Rag2−/− mice injected with either Ad5ROBO4, left three lanes, or Ad5CMV, right three lanes. B. and C. Densitometry analysis of Ad5ROBO4 vector EGFP expression normalized to either VE-cadherin or beta -tubulin. D. Densitometry of AdCMV vector EGFP expression. As AdCMV expression was hepatocyte specific, this blot was only normalized to beta -tubulin. A–D: Representative immunoblots from n = 4 mice injected with either Ad5ROBO 4 or Ad5CMV vectors. Li: liver, KO: kidney orthotopic tumor, SC: subcutaneous tumor. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24376772), licensed under a CC-BY license. Not internally tested by R&D Systems.

Endogenous ROBO4 upregulation despite lower vascular density in orthotopic and xenograft tumors.A. Immunofluorescence of the vascular endothelium in liver (upper panel) and 786-O human renal cell carcinoma (RCC) subcutaneous xenograft tumor (lower panel). B. Vascular area analysis of liver (Li), kidney orthotopic (KO) tumors, and subcutaneous (SC) xenograft tumors (n = 6 mice analyzed). C. Immunoblot of endogenous ROBO4 and the endothelial cell specific VE-cadherin from liver, kidney orthotopic and subcutaneous xenograft 786-O RCC tumors, and from the derivative 786-O cells grown in culture. D. Densitometry analysis of VE-cadherin/tubulin ratio from C mirrors the vascular area determination in B. E. Densitometry analysis of endogenous ROBO4 normalized to VE-cadherin expression reveals a 1.4- to 2-fold increase in SC and KO tumors compared to liver. C–E: Immunoblot and densitometry was repeated twice with two independent sets of protein extracts from two different tumor-bearing mice with essentially the same results. A. Magnification: 100X, Red: endomucin/CD31 antibody cocktail, Blue: DAPI. B. *p<0.05, one way ANOVA with Tukey's correction, mean ± SD. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24376772), licensed under a CC-BY license. Not internally tested by R&D Systems.

Deletion of VE-cadherin in CYP19A1(Tg)Cre; Cdh5fl/fl placentas.(A, B) Immunofluorescence staining and quantification of E12.5 Control and CYP19A1(Tg)Cre; Cdh5fl/fl placentas for VE-cadherin (green) and CK8 (red). Yellow arrowheads indicate VE-cadherin+ trophoblasts, which predominantly line remodeled spiral arteries. White arrowheads indicate VE-cadherin- trophoblasts. Red arrowheads indicate spiral artery endothelial cells (ECs), which are VE-cadherin+ CK8-. VE-cadherin and CK8 colocalized area was divided by total CK8-positive area to determine the extent of VE-cadherin deletion. Note that there are a few VE-cadherin+ trophoblasts in CYP19A1(Tg)Cre; Cdh5fl/fl placentas, however VE-cadherin is deleted from the majority of trophoblasts. The layer of VE-cadherin+ CK8- cells (red arrowheads) in the CYP19A1(Tg)Cre; Cdh5fl/fl placentas are spiral artery endothelial cells that have not been displaced by trophoblasts. Dotted white lines demarcate the decidua and junctional zone (JZ). Positive signal in small, rounded cells in the lumen is the result of erythrocyte autofluorescence. Control n = 4, CYP19A1(Tg)Cre; Cdh5fl/fl n = 3. Scale bars = 100 μm. (C, D) E12.5 placental and embryo weights do not differ between Cre-negative (Cdh5fl/+ or Cdh5fl/fl) and Cre-positive heterozygous (CYP19A1(Tg)Cre; Cdh5fl/fl) controls. Statistical analysis was performed using two-tailed, unpaired Welch’s t-test. Data are shown as means ± SD.Figure 1—figure supplement 1—source data 1.Excel file containing quantification for VE-cadherin expression in trophoblasts, embryo weights, and placenta weights in Figure 1—figure supplement 1.Excel file containing quantification for VE-cadherin expression in trophoblasts, embryo weights, and placenta weights in Figure 1—figure supplement 1. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35486098), licensed under a CC-BY license. Not internally tested by R&D Systems.

VE-cadherin expression is retained in the vasculature of affected organs in CYP19A1(Tg)Cre; Cdh5fl/fl embryos.(A) Immunofluorescence staining of E12.5 Control and CYP19A1(Tg)Cre; Cdh5fl/fl brains for VE-cadherin (green) and Endomucin (red) at sites of hemorrhage. Images in gray scale are VE-cadherin alone. Red arrowheads point to extravascular autofluorescent erythrocytes. Yellow arrowheads point to VE-cadherin+ vessels. Scale bars = 50 μm. (B) Immunofluorescence staining of E12.5 Control and CYP19A1(Tg)Cre; Cdh5fl/fl hearts for VE-cadherin (green) and Endomucin (red). Images in gray scale are VE-cadherin alone. Red arrowheads point to VE-cadherin+ developing coronary vessels. Yellow arrowheads point to VE-cadherin+ endocardium. Scale bars = 50 μm. (C) Immunofluorescence staining of E12.5 Control and CYP19A1(Tg)Cre; Cdh5fl/fl hearts for VE-cadherin (green), Endomucin (red), and LYVE1 (gray). Images in gray scale represent VE-cadherin pixels colocalized with either LYVE1 (liver) or Endomucin (lungs and thorax). Red arrowheads point to LYVE1+VE-cadherin+ liver sinusoidal vessels. Yellow arrowheads point to Endomucin+VE-cadherin+ lung and thoracic blood vessels. Scale bars = 200 μm. (D) Quantification of fold change in VE-cadherin mean fluorescence intensity in the brain, heart, liver, lungs, and thorax.Figure 1—figure supplement 3—source data 1.Excel file containing quantification for VE-cadherin expression in various organs in Figure 1—figure supplement 3.Excel file containing quantification for VE-cadherin expression in various organs in Figure 1—figure supplement 3. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35486098), licensed under a CC-BY license. Not internally tested by R&D Systems.

Microtubules (MT) are indispensable for VEGF-induced cell elongation. a Confluent HUVECs immune labelled for VE-cadherin, alpha -tubulin and Phalloidin-TRITC after VEGF treatment for 24 h or PBS for control, as indicated. Nuclei are stained blue with DAPI. LSM demonstrates MT in control cells evenly distributed throughout the cells, while a few MT are aligned in parallel with JAAF (red arrows). VEGF-induced elongated cells display MT running parallel to the longitudinal cell axis together with stress fibres, and MT are enriched at the leading edge (white arrows; for dynamics compare supplementary Movie 10) (Scale bar: 20 µm). The cropped area displays an interrupted VE-cadherin pattern, MT enrichment, and stress fibres at the cell poles (arrowheads; for dynamics compare Supplementary Movies 10 and 11) (scale bar: 10 µm). b Confluent HUVEC cultures treated with 50 ng ml−1 nocodazole for 4 h and subsequently labelled with VE-cadherin antibody and with Phallodin-TRITC for actin filaments. MT depolymerisation had less effect on the JAAF and VE-cadherin distribution (Scale bar: 20 µm). c–e Confluent HUVECs pre-treated with 50 ng ml−1 nocodazole for 30 min and then treated with VEGF for another 18 h. c Phase-contrast microscopy revealed that nocodazole inhibited VEGF-induced cell elongation (scale bar: 80 µm). Quantification of (d) cell velocity and (e) cell elongation using Fiji software (100 cells were analysed at t = 0, 100 cells at t = 9 h, 81 cells at t = 18 h for nocodazole+VEGF treatment; and 100 cells were analysed at each time point for VEGF treatment, unpaired student’s t test). noco: nocodazole. Representative results from three independent experiments are shown. Error bars indicate ± SEM Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29263363), licensed under a CC-BY license. Not internally tested by R&D Systems.

Polarized distribution of VE-cadherin and actin in sprouting ECs in developing mice retinas. a Laser scanning microscopy (LSM) showing an overview of the front area of a whole-mounted P6 transgenic mouse retina expressing LifeAct-EGFP additionally immune stained with anti-VE-cadherin and anti-ERG antibodies; nuclei were stained with anti-ERG. Tip cell (arrowheads) and adjacent stalk cell (arrows) are indicated. Scale bar: 40 µm. b High-resolution SIM of selected areas 1–3, as indicated in the right panel of a. Shown is one z-plane. (Area 1) a characteristic tip cell with large actin-based filopodia and a cytosolic spotted VE-cadherin pattern. (Area 2) A tip cell/stalk cell junction at the cell pole of elongated cells identifies terminating actin filaments (arrow) and an interrupted VE-cadherin pattern (arrowhead). (Area 3) a stalk cell/stalk cell connection. VE-cadherin plaques are indicated at the cell poles (arrowheads) and a linear VE-cadherin pattern (empty arrowhead) at lateral junctions; parallel actin filaments are also visible. Scale bar: 5 µm. (Area 4) The cropped area depicts an actin-positive JAIL (dotted line, LifeAct-EGFP) with VE-cadherin plaques (dotted line, VE-cadherin staining). Scale bar: 2 µm. c P7 rat retina immune labelled with ARPC2 and VE-cadherin show increased ARPC2 at the cell poles (arrows). Scale bars in the left panels and right panels represent 50 and 15 µm, respectively. d Scheme illustrates the iterative dynamics of VE-cadherin interruption and JAIL formation leading to VE-cadherin plaques in sprouting ECs. The VE-cadherin dynamics was particularly pronounced at the cell poles, while the lateral junctions showed moderate dynamics Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29263363), licensed under a CC-BY license. Not internally tested by R&D Systems.

JAIL formation&cell migration are blocked by Rac inhibition&VE-cadherin overexpression in scratch assay. a–f HUVECs scratched, allowed to grow for 5 h,&labelled for VE-cadherin&Phalloidin-TRITC. a Overviews of the migrating front (left upper)&centre area (left lower). (Area 1) interrupted VE-cadherin that co-localise with filopodia-like actin filaments (arrows). (Area 2) Large JAIL (arrowheads) at cell pole. (Area 3) small JAIL (arrowheads) at lateral junctions. (Area 4) Polygonal cells in the centre area. Scale bars represent 60 µm&15 µm in the overview&cropped images respectively. b, c Comparison of cell perimeter&Rel-VEcad-C in front&centre ECs. Quantification of (d) JAIL number&(e) JAIL size in front (n = 115 cells)&centre cells (n = 186 cells). f JAIL size at cell poles&lateral junctions in front ECs (n = 115 cells). P value was determined by unpaired student’s t test. Image collected & cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29263363), licensed under a CC-BY license. Not internally tested by R&D Systems.

Polarized JAIL dynamics during sprouting angiogenesis in fibrin angiogenesis assay using EGFP-p20 expressing HUVECs.f Overview&Z-projections of vessel sprouts in fibrin angiogenesis assays 5 days after seeding; cells fixed&labelled with Phalloidin-TRITC&VE-cadherin. (cropped areas) JAIL are indicated at cell poles by the appearance of large VE-cadherin plaques (arrows) that co-localise with the actin network (arrows), whereas small VE-cadherin plaques appear at lateral junctions (arrowhead). Error bars represent ± SEM; scale bars indicate 50&10 µm in the overview&cropped areas, respectively Image collected & cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29263363), licensed under a CC-BY license. Not internally tested by R&D Systems.

Acquisition of endothelial markers upon trophoblast differentiation is associated with down-regulation in Hes1.(A) Western blot analysis for HES1 and endothelial cell–specific proteins CDH5, PECAM1, and ENG using cell lysates from TS and TC. (A, B) Densitometric analysis of the proteins from blots in (A) using NIH ImageJ software after normalization with GAPDH. (C) Quantitative real-time PCR of Hes1 using RNA from TS cells transfected with either scrambled or Hes1 siRNA. (D, E) Quantitative real-time PCR of Cdh5 (D) and endoglin (E) using RNA from TS cells transfected with either scrambled or Hes1 siRNA. (F) Western blot analysis of HES1, CDH5, PECAM1, and ENG using cell lysates from TS cells transfected with either 100 nM scrambled or Hes1 siRNA followed by induction of differentiation till day 2. (F, G) Densitometric analysis of the proteins from (F) using NIH ImageJ software after normalization with GAPDH. Data are representative of three independent biological replicates. Error bars represent SEM. *P < 0.5, **P < 0.01.Source data are available for this figure. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36574992), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

, , ,

Applications: , , ,

Host:

Goat Polyclonal

Host: Goat Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	AF1002U-100UG
Alexa Fluor 405	AF1002V-100UG
Alexa Fluor 488	AF1002G-100UG
Alexa Fluor 532	AF1002X-100UG
Alexa Fluor 594	AF1002T-100UG
Alexa Fluor 647	AF1002R-100UG
Alexa Fluor 700	AF1002N-100UG
Alexa Fluor 750	AF1002S-100UG
Alexa Fluor Plus 405	AF1002AFP405-100UG
Alexa Fluor Plus 488	AF1002AFP488-100UG
Alexa Fluor Plus 555	AF1002AFP555-100UG
Alexa Fluor Plus 594	AF1002AFP594-100UG
Alexa Fluor Plus 647	AF1002AFP647-100UG
Alexa Fluor Plus 680	AF1002AFP680-100UG
Allophycocyanin	AF1002A
Biotin	BAF1002
CoraFluor 1	AF1002CL1
DyLight 350	AF1002D
DyLight 405	AF1002E
DyLight 488	AF1002K
DyLight 550	AF1002L
DyLight 594	AF1002M
DyLight 650	AF1002W
DyLight 680	AF1002Y
DyLight 755	AF1002Z
FITC	AF1002F
HRP	AF1002H
Janelia Fluor 525	AF1002JF525
Janelia Fluor 549	AF1002I
Janelia Fluor 646	AF1002J
Janelia Fluor 669	AF1002JF669
PE	AF1002P
PerCP	AF1002C
mFluor Violet 450 SE	AF1002MFV450
mFluor Violet 500 SE	AF1002MFV500
mFluor Violet 610 SE	AF1002MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF1002-SP

compare

(select up to 3 products from this page to compare)

AF938

VE-Cadherin Antibody [Unconjugated]

(75 Publications)

100 μg

AF938

HAF017). A specific band was detected for VE-Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox">

Western blot shows lysate of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 0.25 µg/mL of Goat Anti-Human VE-Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF938) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (<a class=

HAF017). A specific band was detected for VE-Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysate of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 0.25 µg/mL of Goat Anti-Human VE-Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF938) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (HAF017). A specific band was detected for VE-Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

NL001) and counterstained with DAPI (blue). Specific staining was localized to the plasma membrane. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox">

VE-Cadherin was detected in immersion fixed HUVEC human umbilical vein endothelial cells using Goat Anti-Human VE-Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF938) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; <a class=

NL001) and counterstained with DAPI (blue). Specific staining was localized to the plasma membrane. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />

AB-108-C, open histogram) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (F0108). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox">

HUVEC human umbilical vein endothelial cells were stained with Goat Anti-Human VE-Cadherin Monoclonal Antibody (AF938, filled histogram) or isotype control antibody (<a class=

AB-108-C, open histogram) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (F0108). View our protocol for Staining Membrane-associated Proteins." class="big_thumb" />

Treatment with an NO donor or Claudin-1 inhibition improved barrier integrity in ASL-deficient HBMECs.(A) TEER measurement in HBMECs treated with 0, 10, or 25 μM of S-nitroso-N-acetylpenicillamine (SNAP), an NO donor, 48 hours (hr) after subculture (n = 3). (B) Comparison of TEER levels in HBMECs treated with 25 μM of either N-acetylpenicillamine (NAP) or SNAP 48 hr after subculture. SNAP or NAP was added daily, starting 24 hr after subculture (n = 3). (C) Western blot analysis and (D) quantification investigating the effects of SNAP (25 μM) on expression of ASL, CLDN5, CLDN1, and VE-Cadherin in ASL-deficient HBMECs (n = 3). SNAP was added to the treatment group 24 hr prior to protein extraction. (E) Relative mRNA expression of CLDN1 in HBMECs 48 hr after transfection with siControl, siASL, or both siASL and siCLDN1 (n = 3). (F) Western blot analysis and (G) quantification to assess ASL, CLDN5, and CLDN1 protein level in HBMECs 48 hr after siRNA transfection (n = 3). Protein abundance was normalized to alpha -Tubulin level in D and G. (H) TEER measurement to investigate the effects of SNAP (25 μM) or siRNA-mediated inhibition of CLDN1 on paracellular barrier integrity of ASL-deficient HBMECs. Bar graphs represent mean values while error bars represent the standard deviation. *P < 0.05, **P < 0.01, and ***P < 0.001. One-way ANOVA, multiple comparisons. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37490345), licensed under a CC-BY license. Not internally tested by R&D Systems.

Simple Western lane view shows lysates of HUVEC human umbilical vein endothelial cells, loaded at 0.2 mg/mL. A specific band was detected for VE‑Cadherin at approximately 162 kDa (as indicated) using 12.5 µg/mL of Goat Anti-Human VE‑Cadherin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF938) . This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

ASL knockdown in HBMECs leads to reduced NO signaling, decreased paracellular permeability, and dysregulated expression of BBB-associated genes.(A) Relative mRNA expression of ASL in HBMECs 2 days after transfection with control and ASL siRNAs (siControl and siASL) (n = 3). (B) Intracellular levels of NO in siControl and siASL-transfected HBMECs as measured by DAF-FM diacetate fluorescence assay (n = 9). (C) Intracellular cGMP levels in siControl and siASL-transfected HBMECs as measured by ELISA (n = 5). (D) Quantitative analysis of TEER level at 1–3 days after transfected HBMECs were seeded on Transwell inserts (n = 3). (E) Relative mRNA expression of CLDN5, CDH5, TJP1, OCLN, and CLDN1 in HBMECs 2 days after siRNA-mediated knockdown (n = 3). (F) Western blot analysis of ASL, CLDN1, OCLN, CLDN5, and VE-Cadherin protein levels in HBMECs 2 days after siControl and siASL transfection. Samples were run on 2 separate gels, and alpha -Tubulin was used as the internal control (n = 3). (G) Protein abundance was quantitatively measured after normalization to alpha -Tubulin level. Bar graphs represent mean values while error bars represent the standard deviation. *P < 0.05, **P < 0.01, and ***P < 0.001. Student’s t test. A.U., arbitrary units. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/37490345), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, , , ,

Applications: , , , ,

Host:

Goat Polyclonal

Host: Goat Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	AF938U-100UG
Alexa Fluor 405	AF938V-100UG
Alexa Fluor 488	AF938G-100UG
Alexa Fluor 532	AF938X-100UG
Alexa Fluor 594	AF938T-100UG
Alexa Fluor 647	AF938R-100UG
Alexa Fluor 700	AF938N-100UG
Alexa Fluor 750	AF938S-100UG
Alexa Fluor Plus 405	AF938AFP405-100UG
Alexa Fluor Plus 488	AF938AFP488-100UG
Alexa Fluor Plus 555	AF938AFP555-100UG
Alexa Fluor Plus 594	AF938AFP594-100UG
Alexa Fluor Plus 647	AF938AFP647-100UG
Alexa Fluor Plus 680	AF938AFP680-100UG
Allophycocyanin	AF938A
Biotin	BAF938
CoraFluor 1	AF938CL1
DyLight 350	AF938D
DyLight 405	AF938E
DyLight 488	AF938K
DyLight 550	AF938L
DyLight 594	AF938M
DyLight 650	AF938W
DyLight 680	AF938Y
DyLight 755	AF938Z
FITC	AF938F
HRP	AF938H
Janelia Fluor 525	AF938JF525
Janelia Fluor 549	AF938I
Janelia Fluor 646	AF938J
Janelia Fluor 669	AF938JF669
PE	AF938P
PerCP	AF938C
mFluor Violet 450 SE	AF938MFV450
mFluor Violet 500 SE	AF938MFV500
mFluor Violet 610 SE	AF938MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	AF938-SP

compare

(select up to 3 products from this page to compare)

MAB9381

VE-Cadherin Antibody (123413) [Unconjugated]

(29 Publications)

100 μg

MAB9381

HAF018). A specific band was detected for VE-Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox">

Western blot shows lysate of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human VE-Cadherin Monoclonal Antibody (Catalog # MAB9381) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (<a class=

HAF018). A specific band was detected for VE-Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." alt="Western blot shows lysate of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/mL of Mouse Anti-Human VE-Cadherin Monoclonal Antibody (Catalog # MAB9381) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (HAF018). A specific band was detected for VE-Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_thumb" />

NL007) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox">

VE-Cadherin was detected in immersion fixed HUVEC cells using Mouse Anti-Human VE-Cadherin Monoclonal Antibody (Catalog # MAB9381) at 0.5 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # <a class=

NL007) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />

MAB004, open histogram) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (F0101B). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox">

HUVEC human umbilical vein endothelial cells were stained with Mouse Anti-Human VE-Cadherin Monoclonal Antibody (Catalog # MAB9381, filled histogram) or isotype control antibody (<a class=

MAB004, open histogram) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (F0101B). View our protocol for Staining Membrane-associated Proteins." class="big_thumb" />

<b>Biological Strategies Validation. </b>Immortalized HAECs retain phenotypic and functional characteristics of primary cells. (A) (Top) Immortalized HAEC confluent monolayers stained with CD31-AF488 antibody (green) and DAPI (blue). (Bottom) Flow cytometry histogram plots of primary or immortalized HAECs labeled with CD31-AF488 antibody. Secondary antibody only (dashed line) and nonstained cells (dotted line) were used as negative controls. (B) (Top) Immortalized HAEC confluent monolayers stained with VE-cadherin-AF488 (green) antibody, Acti-Stain 555 phalloidin (red), and DAPI (blue). (Bottom) Flow cytometry histogram plots of immortalized HAECs labeled with VE-cadherin-AF488 and ZO-1-AF647 antibodies. Secondary antibody only (dashed line) was used as a negative control. (C) Tube forming assay of primary (top) and immortalized (bottom) HAECs at 0 h and 8 h after seeding in Matrigel-coated wells. (D) Acetylated low-density lipoprotein (Ac-LDL) uptake assay of primary HAECs (top), immortalized HAECs (middle), and fibroblasts (negative control; bottom) treated with fluorescently labeled Ac-LDL (red) for 2.5 h and stained with DAPI (blue). (E) IL-8 detection in culture supernatants 24 h after treatment of primary or immortalized HAECs with increasing concentrations of TNF-alpha , IFN-gamma , or IL-6. (F) IL-8 detection in culture supernatants 24 h after treatment of immortalized HAECs with increasing concentrations of IL-2 or IL-1. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29229737), licensed under a CC-BY license. Not internally tested by R&D Systems.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, , ,

Applications: , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	FAB9381U-100UG
Alexa Fluor 405	FAB9381V-100UG
Alexa Fluor 488	FAB9381G-100UG
Alexa Fluor 532	FAB9381X
Alexa Fluor 594	FAB9381T-100UG
Alexa Fluor 647	FAB9381R-100UG
Alexa Fluor 700	FAB9381N-100UG
Alexa Fluor 750	FAB9381S-100UG
Alexa Fluor Plus 405	FAB9381AFP405-100UG
Alexa Fluor Plus 488	FAB9381AFP488-100UG
Alexa Fluor Plus 555	FAB9381AFP555-100UG
Alexa Fluor Plus 594	FAB9381AFP594-100UG
Alexa Fluor Plus 647	FAB9381AFP647-100UG
Alexa Fluor Plus 680	FAB9381AFP680-100UG
Allophycocyanin	FAB9381A-100
Allophycocyanin	FAB9381A-025
Allophycocyanin/Cy7	FAB9381APCCY7
Biotin	BAM9381
CoraFluor 1	FAB9381CL1
DyLight 350	FAB9381D
DyLight 405	FAB9381E
DyLight 488	FAB9381K
DyLight 550	FAB9381L
DyLight 594	FAB9381M
DyLight 650	FAB9381W
DyLight 680	FAB9381Y
DyLight 755	FAB9381Z
FITC	FAB9381F
HRP	FAB9381H
Janelia Fluor 525	FAB9381JF525
Janelia Fluor 549	FAB9381I
Janelia Fluor 646	FAB9381J
Janelia Fluor 669	FAB9381JF669
PE/Atto594	FAB9381PEATT594
PE/Cy5.5	FAB9381PECY55
PE/Cy7	FAB9381PECY7
PerCP	FAB9381C
mFluor Violet 450 SE	FAB9381MFV450
mFluor Violet 500 SE	FAB9381MFV500
mFluor Violet 610 SE	FAB9381MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	MAB9381-SP
Carrier Free	FAB9381A-100
Carrier Free	FAB9381A-025
Carrier Free	FAB9381N-100UG
Carrier Free	FAB9381G-100UG
Carrier Free	FAB9381V-100UG
Carrier Free	FAB9381U-100UG
Carrier Free	FAB9381T-100UG
Carrier Free	FAB9381S-100UG
Carrier Free	FAB9381R-100UG

compare

(select up to 3 products from this page to compare)

NBP1-43347

VE-Cadherin Antibody (BV14) - BSA Free

(7 Publications)

0.1 mg

NBP1-43347

MAP4K4 deficiency induces TGF beta /smad signaling and EndMT via activation of integrin beta 1. (a) HMVECs were transfected with MAP4K4 siRNA (100 nM) for 48 h. Next, the cells were treated with or without AcSDKP for 2 h. The p-smad3/smad3 pathway was analyzed by western blot. Densitometric analysis of the p-smad3/smad3 levels was performed, with n=3 for each group. (b) HMVECs were treated with MAP4K4 siRNA for 48 h with or without AcSDKP treatment. The VE-cadherin, CD31, FSP1, SM22 alpha and vimentin protein levels were analyzed by western blot. (c) HMVECs were transfected with MAP4K4 siRNA for 48 h in the presence or absence of TGF beta 2 with or without AcSDKP. The integrin beta 1 level was analyzed by western blot Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

AcSDKP suppresses TGF beta /smad signaling and EndMT through the FGFR1/FRS2 pathway. (a) HMVECs were treated with N-FGFR1 for 48 h, and the FGFR1, TGF beta R1 and TGF beta R2 protein levels were analyzed by western blot. (b) HMVECs were treated with TGF beta 2 in the presence or absence of N-FGFR1 for 15 min with or without AcSDKP preincubation. The p-smad3 and TGF beta R1 protein levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3 and TGF beta R1/ beta -actin levels (n=3) in each group was performed. (c) HMVECs were incubated with either N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without preincubation with AcSDKP for 2 h or with N-FGFR1 in the presence or absence of TGF beta 2 for 48 h with or without 24 h of incubation with FGF2 (50 ng/ml). The CD31, SM22 alpha , FSP1 and alpha -SMA protein levels were analyzed by western blot. (d) HMVECs were transfected with FRS2 siRNA (100 nM) for 48 h with or without AcSDKP preincubation. The VE-cadherin, FSP1, vimentin, SM22 alpha and p-smad3 levels were analyzed by western blot. (e) HMVECs were treated with N-FGFR1 for 48 h or 15 min in the presence or absence of N-TGF beta (1, 2, 3) (1.0 μg/ml). The CD31, VE-cadherin, SM22 alpha , FSP1, TGF beta R1, TGF beta R2 and p-smad3 levels were analyzed by western blot Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Spike-induced degradation of endothelial junctional proteins is greater in arteries of diabetic mice. (A) Representative Western blot indicating expression of endothelial junctional proteins in arteries isolated from control or diabetic mice. (B) Mean data indicating fold change in protein expression. n = 4 for each, *P < 0.05 vs. untreated control, δP < 0.05 vs. untreated diabetic, #P < 0.05 vs. Spike-treated control. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/34179146), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Either FGF19 or FGF21 enhanced the inhibitory effect of AcSDKP on EndMT and MEK/ERK pathway. In the presence of AcSDKP, HMVECs were stimulated by TGF beta 2 with or without FGF19 (100 ng·mL−1) or FGF21 (100 ng·mL−1) treatment. The levels of VE‐cadherin/ beta ‐Actin, alpha ‐SMA/ beta ‐Actin, P‐ERK/T‐ERK, and P‐MEK/T‐MEK were examined by western blot analysis (A, C) and quantified (B, D). The data represent mean +/- SD. Three independent experiments were performed for each result. ANOVA with Tukey's multiple comparisons test was applied. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30972974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

KLB deficiency led to EndMT in HMVECs. (A) Subconfluent HMVECs were transfected with KLB siRNA or control siRNA. Six hours later, the medium was replaced with an experimental medium, followed by N‐FGFR1 (1.5 mg·mL−1) treatment. At 48 h, the cells were harvested for western blot analysis. The results are from three repeated experiments. (B) The same treated HMVECs (as in A) cultured on 8‐well culture slides were subjected to immunofluorescence staining with an anti‐ alpha ‐SMA antibody and DAPI (scale bar, 100 μm). Six different fields were observed for each slide. (C) HMVECs with or without preincubation with AcSDKP (100 nm) for 2 h were transfected with KLB siRNA or control siRNA for 48 h. The expression of EndMT markers, including VE‐cadherin, alpha ‐SMA, vimentin, and SM22 alpha , was assessed by western blotting and quantified (D) by imagej software (GE Healthcare Life Sciences, Uppsala, Sweden). The data represent mean +/- SD and are representative of three independent experiments. One‐way ANOVA with Tukey's multiple comparisons test was used for statistical analysis. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/30972974), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

SARS-CoV-2 spike protein (Spike) increases endothelial permeability by downregulation of junctional proteins in diabetic endothelial cells. (A) Endothelial transwell permeability assay, mean data expressed as fold change. n = 6 for each, *P < 0.05 vs. untreated control, δP < 0.05 vs. untreated diabetic, #P < 0.05 vs. Spike-treated control. (B) Representative Western blot indicating expression of endothelial junctional proteins in endothelial cell culture with or without Spike treatment. (C) Mean data indicating fold change in protein expression. n = 6 for each, *P < 0.05 vs. untreated control, δP < 0.05 vs. untreated diabetic, #P < 0.05 vs. Spike-treated control. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/34179146), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu

Species Glossary

Reactivity: Hu, Mu

Applications:

, , ,

Applications: , , ,

Host:

Rat Monoclonal

Host: Rat Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP1-43347AF350
Alexa Fluor 405	NBP1-43347AF405
Alexa Fluor 488	NBP1-43347AF488
Alexa Fluor 532	NBP1-43347AF532
Alexa Fluor 594	NBP1-43347AF594
Alexa Fluor 647	NBP1-43347AF647
Alexa Fluor 700	NBP1-43347AF700
Alexa Fluor 750	NBP1-43347AF750
Alexa Fluor Plus 405	NBP1-43347AFP405
Alexa Fluor Plus 488	NBP1-43347AFP488
Alexa Fluor Plus 555	NBP1-43347AFP555
Alexa Fluor Plus 594	NBP1-43347AFP594
Alexa Fluor Plus 647	NBP1-43347AFP647
Alexa Fluor Plus 680	NBP1-43347AFP680
Allophycocyanin	NBP1-43347APC
Biotin	NBP1-43347B
CoraFluor 1	NBP1-43347CL1
DyLight 350	NBP1-43347UV
DyLight 405	NBP1-43347V
DyLight 488	NBP1-43347G
DyLight 550	NBP1-43347R
DyLight 594	NBP1-43347DL594
DyLight 650	NBP1-43347C
DyLight 680	NBP1-43347FR
DyLight 755	NBP1-43347IR
FITC	NBP1-43347F
HRP	NBP1-43347H
Janelia Fluor 525	NBP1-43347JF525
Janelia Fluor 549	NBP1-43347JF549
Janelia Fluor 646	NBP1-43347JF646
Janelia Fluor 669	NBP1-43347JF669
PE	NBP1-43347PE
PerCP	NBP1-43347PCP
mFluor Violet 450 SE	NBP1-43347MFV450
mFluor Violet 500 SE	NBP1-43347MFV500
mFluor Violet 610 SE	NBP1-43347MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP1-43347-0.5mg
BSA Free	NBP1-43347-0.025mg

compare

(select up to 3 products from this page to compare)

NB600-1409

VE-Cadherin Antibody (BV9) - Azide Free

(7 Publications)

0.05 mg

NB600-1409

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Conjugate:

Unconjugated

compare

(select up to 3 products from this page to compare)

MAB11663

VE-Cadherin Antibody (1098251) [Unconjugated]

100 μg

MAB11663

HAF018). A specific band was detected for VE‑Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1." class="big_lightbox">

Western Blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 2 µg/ml of Mouse Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11663) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # <a class=

HAF018). A specific band was detected for VE‑Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1." alt="Western Blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 2 µg/ml of Mouse Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11663) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF018). A specific band was detected for VE‑Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1." class="big_thumb" />

Simple Western shows lysates of HUVEC human umbilical vein endothelial cells, loaded at 0.5 mg/ml. A specific band was detected for VE‑Cadherin at approximately 153 kDa (as indicated) using 20 µg/mL of Mouse Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11663). This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cell membrane of endothelial cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

VE‑Cadherin was detected in immersion fixed paraffin-embedded sections of human kidney using Mouse Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11663) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # <a class=

VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cell membrane of endothelial cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cell membrane of endothelial cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

VE‑Cadherin was detected in immersion fixed paraffin-embedded sections of human cervix using Mouse Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11663) at 5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte™ HRP Polymer Antibody (Catalog # <a class=

VC001) or the HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the cell membrane of endothelial cells. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

NL007) and counterstained with DAPI (blue). Specific staining was localized to the cell membrane of HUVEC cells. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox">

VE‑Cadherin was detected in immersion fixed HUVEC human umbilical vein endothelial cells (Positive) and absent in MCF‑7 human breast cancer cell line (Negative) using Mouse Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11663) at 8 µg/ml for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # <a class=

NL007) and counterstained with DAPI (blue). Specific staining was localized to the cell membrane of HUVEC cells. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, , ,

Applications: , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	FAB11663U-100UG
Alexa Fluor 405	FAB11663V-100UG
Alexa Fluor 488	FAB11663G-100UG
Alexa Fluor 532	FAB11663X-100UG
Alexa Fluor 594	FAB11663T-100UG
Alexa Fluor 647	FAB11663R-100UG
Alexa Fluor 700	FAB11663N-100UG
Alexa Fluor 750	FAB11663S-100UG
Alexa Fluor Plus 405	FAB11663AFP405-100UG
Alexa Fluor Plus 488	FAB11663AFP488-100UG
Alexa Fluor Plus 555	FAB11663AFP555-100UG
Alexa Fluor Plus 594	FAB11663AFP594-100UG
Alexa Fluor Plus 647	FAB11663AFP647-100UG
Alexa Fluor Plus 680	FAB11663AFP680-100UG
Allophycocyanin	FAB11663A
Biotin	FAB11663B
CoraFluor 1	FAB11663CL1
DyLight 350	FAB11663D
DyLight 405	FAB11663E
DyLight 488	FAB11663K
DyLight 550	FAB11663L
DyLight 594	FAB11663M
DyLight 650	FAB11663W
DyLight 680	FAB11663Y
DyLight 755	FAB11663Z
FITC	FAB11663F
HRP	FAB11663H
Janelia Fluor 525	FAB11663JF525
Janelia Fluor 549	FAB11663I
Janelia Fluor 646	FAB11663J
Janelia Fluor 669	FAB11663JF669
PE	FAB11663P
PerCP	FAB11663C
mFluor Violet 450 SE	FAB11663MFV450
mFluor Violet 500 SE	FAB11663MFV500
mFluor Violet 610 SE	FAB11663MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	MAB11663-SP

compare

(select up to 3 products from this page to compare)

MAB1002

VE-Cadherin Antibody (162709) [Unconjugated]

(4 Publications)

100 μg

MAB1002

MAB0061, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG Secondary Antibody (Catalog # F0105B). View our protocol for Staining Membrane-associated Proteins." class="big_lightbox">

MAB0061, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG Secondary Antibody (Catalog # F0105B). View our protocol for Staining Membrane-associated Proteins." alt="bEnd.3 mouse endothelioma cell line was stained with Rat Anti-Mouse VE-Cadherin Monoclonal Antibody (Catalog # MAB1002, filled histogram) or isotype control antibody (Catalog # MAB0061, open histogram), followed by Phycoerythrin-conjugated Anti-Rat IgG Secondary Antibody (Catalog # F0105B). View our protocol for Staining Membrane-associated Proteins." class="big_thumb" />

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

, ,

Applications: , ,

Host:

Rat Monoclonal

Host: Rat Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	FAB1002U-100UG
Alexa Fluor 405	FAB1002V-100UG
Alexa Fluor 488	FAB1002G-100UG
Alexa Fluor 532	FAB1002X
Alexa Fluor 594	FAB1002T-100UG
Alexa Fluor 647	FAB1002R-100UG
Alexa Fluor 700	FAB1002N-100UG
Alexa Fluor 750	FAB1002S-100UG
Alexa Fluor Plus 405	FAB1002AFP405-100UG
Alexa Fluor Plus 488	FAB1002AFP488-100UG
Alexa Fluor Plus 555	FAB1002AFP555-100UG
Alexa Fluor Plus 594	FAB1002AFP594-100UG
Alexa Fluor Plus 647	FAB1002AFP647-100UG
Alexa Fluor Plus 680	FAB1002AFP680-100UG
Allophycocyanin	FAB1002A
Allophycocyanin/Cy7	FAB1002APCCY7
Biotin	FAB1002B
CoraFluor 1	FAB1002CL1
DyLight 350	FAB1002D
DyLight 405	FAB1002E
DyLight 488	FAB1002K
DyLight 550	FAB1002L
DyLight 594	FAB1002M
DyLight 650	FAB1002W
DyLight 680	FAB1002Y
DyLight 755	FAB1002Z
FITC	FAB1002F
HRP	FAB1002H
Janelia Fluor 525	FAB1002JF525
Janelia Fluor 549	FAB1002I
Janelia Fluor 646	FAB1002J
Janelia Fluor 669	FAB1002JF669
PE/Atto594	FAB1002PEATT594
PE/Cy5.5	FAB1002PECY55
PE/Cy7	FAB1002PECY7
PerCP	FAB1002C
mFluor Violet 450 SE	FAB1002MFV450
mFluor Violet 500 SE	FAB1002MFV500
mFluor Violet 610 SE	FAB1002MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	FAB1002A
Carrier Free	MAB1002-SP
Carrier Free	FAB1002V-100UG
Carrier Free	FAB1002U-100UG
Carrier Free	FAB1002T-100UG
Carrier Free	FAB1002S-100UG
Carrier Free	FAB1002R-100UG
Carrier Free	FAB1002N-100UG
Carrier Free	FAB1002G-100UG

compare

(select up to 3 products from this page to compare)

MAB11726

VE-Cadherin Antibody (3340A) [Unconjugated]

100 μg

MAB11726

HAF008). A specific band was detected for VE‑Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1." class="big_lightbox">

Western Blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/ml of Rabbit Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11726) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # <a class=

HAF008). A specific band was detected for VE‑Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1." alt="Western Blot shows lysates of HUVEC human umbilical vein endothelial cells. PVDF membrane was probed with 1 µg/ml of Rabbit Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11726) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for VE‑Cadherin at approximately 125 kDa (as indicated). This experiment was conducted under reducing conditions and using Western Blot Buffer Group 1." class="big_thumb" />

VC003) or the HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

VE‑Cadherin was detected in immersion fixed paraffin-embedded sections of human prostate cancer using Rabbit Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11726) at 0.5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody (Catalog # <a class=

VC003) or the HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

VC003) or the HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

VE‑Cadherin was detected in immersion fixed paraffin-embedded sections of human kidney using Rabbit Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11726) at 0.5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody (Catalog # <a class=

VC003) or the HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

VC003) or the HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_lightbox">

VE‑Cadherin was detected in immersion fixed paraffin-embedded sections of human placenta using Rabbit Anti-Human VE‑Cadherin Monoclonal Antibody (Catalog # MAB11726) at 0.5 µg/ml for 1 hour at room temperature followed by incubation with the Anti-Rabbit IgG VisUCyte™ HRP Polymer Antibody (Catalog # <a class=

VC003) or the HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using VisUCyte Antigen Retrieval Reagent-Basic (Catalog # VCTS021). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to the membrane. View our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents." class="big_thumb" />

NL004) and counterstained with DAPI (blue). Specific staining was localized to the cell surface of HUVEC cells. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox">

NL004) and counterstained with DAPI (blue). Specific staining was localized to the cell surface of HUVEC cells. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_thumb" />

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, ,

Applications: , ,

Host:

Rabbit Monoclonal

Host: Rabbit Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	FAB11726U-100UG
Alexa Fluor 488	FAB11726G-100UG
Alexa Fluor 532	FAB11726X-100UG
Alexa Fluor 594	FAB11726T-100UG
Alexa Fluor 647	FAB11726R-100UG
Alexa Fluor 700	FAB11726N-100UG
Alexa Fluor 750	FAB11726S-100UG
Alexa Fluor Plus 405	FAB11726AFP405-100UG
Alexa Fluor Plus 488	FAB11726AFP488-100UG
Alexa Fluor Plus 555	FAB11726AFP555-100UG
Alexa Fluor Plus 594	FAB11726AFP594-100UG
Alexa Fluor Plus 647	FAB11726AFP647-100UG
Alexa Fluor Plus 680	FAB11726AFP680-100UG
Allophycocyanin	FAB11726A
Biotin	FAB11726B
CoraFluor 1	FAB11726CL1
DyLight 350	FAB11726D
DyLight 405	FAB11726E
DyLight 488	FAB11726K
DyLight 550	FAB11726L
DyLight 594	FAB11726M
DyLight 650	FAB11726W
DyLight 680	FAB11726Y
DyLight 755	FAB11726Z
FITC	FAB11726F
HRP	FAB11726H
Janelia Fluor 525	FAB11726JF525
Janelia Fluor 549	FAB11726I
Janelia Fluor 646	FAB11726J
Janelia Fluor 669	FAB11726JF669
PE	FAB11726P
PerCP	FAB11726C
mFluor Violet 450 SE	FAB11726MFV450
mFluor Violet 500 SE	FAB11726MFV500
mFluor Violet 610 SE	FAB11726MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Carrier Free	MAB11726-SP

compare

(select up to 3 products from this page to compare)

DCADV0

Human VE-Cadherin Quantikine ELISA Kit

(5 Publications)

1 Kit

DCADV0

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

Applications:

compare

(select up to 3 products from this page to compare)

NBP3-20089

Mouse VE-Cadherin ELISA Kit (Colorimetric)

1 Kit

NBP3-20089

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

Applications:

Standard Curve:

0.16 - 10 ng/mL

Sensitivity:

0.10 ng/mL

Sample Type:

Serum, plasma and other biological fluids

compare

(select up to 3 products from this page to compare)

NBP1-43348

VE-Cadherin Antibody (BV13) - BSA Free

(1 Publication)

0.1 mg

NBP1-43348

Reactivity:

Mu

Species Glossary

Reactivity: Mu

Applications:

, , ,

Applications: , , ,

Host:

Rat Monoclonal

Host: Rat Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP1-43348AF350
Alexa Fluor 405	NBP1-43348AF405
Alexa Fluor 488	NBP1-43348AF488
Alexa Fluor 532	NBP1-43348AF532
Alexa Fluor 594	NBP1-43348AF594
Alexa Fluor 647	NBP1-43348AF647
Alexa Fluor 700	NBP1-43348AF700
Alexa Fluor 750	NBP1-43348AF750
Alexa Fluor Plus 405	NBP1-43348AFP405
Alexa Fluor Plus 488	NBP1-43348AFP488
Alexa Fluor Plus 555	NBP1-43348AFP555
Alexa Fluor Plus 594	NBP1-43348AFP594
Alexa Fluor Plus 647	NBP1-43348AFP647
Alexa Fluor Plus 680	NBP1-43348AFP680
Allophycocyanin	NBP1-43348APC
Allophycocyanin/Cy7	NBP1-43348APCCY7
Biotin	NBP1-43579-0.1mg
Biotin	NBP1-43579-0.025mg
CoraFluor 1	NBP1-43348CL1
DyLight 350	NBP1-43348UV
DyLight 405	NBP1-43348V
DyLight 488	NBP1-43348G
DyLight 550	NBP1-43348R
DyLight 594	NBP1-43348DL594
DyLight 650	NBP1-43348C
DyLight 680	NBP1-43348FR
DyLight 755	NBP1-43348IR
FITC	NBP1-43348F
HRP	NBP1-43348H
Janelia Fluor 525	NBP1-43348JF525
Janelia Fluor 549	NBP1-43348JF549
Janelia Fluor 646	NBP1-43348JF646
Janelia Fluor 669	NBP1-43348JF669
PE	NBP1-43348PE
PE/Atto594	NBP1-43348PEATT594
PE/Cy5.5	NBP1-43348PECY55
PE/Cy7	NBP1-43348PECY7
PerCP	NBP1-43348PCP
mFluor Violet 450 SE	NBP1-43348MFV450
mFluor Violet 500 SE	NBP1-43348MFV500
mFluor Violet 610 SE	NBP1-43348MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP1-43348-0.5mg
BSA Free	NBP1-43348-0.05mg

compare

(select up to 3 products from this page to compare)

938-VC

Recombinant Human VE-Cadherin Fc Chimera His-tag Protein, CF

(4 Publications)

50 μg

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

Applications:

compare

(select up to 3 products from this page to compare)

At	=	A. thaliana	SyHa	=	Golden Syrian Hamster
All	=	All Species	Ha	=	Hamster
An	=	Animal	Hu	=	Human
ArHa	=	Armenian Hamster	I	=	Insect
Av	=	Avian	Ll	=	Llama
Bb	=	Baboon	Ma	=	Mammal
Ba	=	Bacteria	Mk	=	Monkey
Bv	=	Bovine	Mu	=	Mouse
Ca	=	Canine	Multi	=	Multi-species
Ce	=	C. Elegans	NA	=	Non-species specific
Ch	=	Chicken	Or	=	Orangutan
ChHa	=	Chinese Hamster	Pl	=	Plant
Cm	=	Cynomolgus Monkey	Pm	=	Primate
Do	=	Donkey	Po	=	Porcine
Dr	=	Drosophilia	Rb	=	Rabbit
Ec	=	E. Coli	Rt	=	Rat
Eq	=	Equine	RM	=	Rhesus Macaque
Fe	=	Feline	Sh	=	Sheep
Ft	=	Ferret	Vb	=	Vertebrate
Fi	=	Fish	Vi	=	Virus
Fu	=	Fungi	Xp	=	Xenopus
Ge	=	Gerbil	Ye	=	Yeast
GP	=	Guinea Pig	Ze	=	Zebrafish
Gt	=	Goat

Category

Protein/Target

Applications

Reactivity

Citation

Reviews

Host

Available Conjugates

Format

Modification

Clonality

Clone

Gene Symbol

Images Type

Isotype

Preservative

Protein Or Peptide

Research Areas

Has Sample Size

Promotional Item

Species Glossary

VE-Cadherin Antibody [Unconjugated]

VE-Cadherin Antibody [Unconjugated]

VE-Cadherin Antibody (123413) [Unconjugated]

VE-Cadherin Antibody (BV14) - BSA Free

VE-Cadherin Antibody (BV9) - Azide Free

VE-Cadherin Antibody (1098251) [Unconjugated]

VE-Cadherin Antibody (162709) [Unconjugated]

VE-Cadherin Antibody (3340A) [Unconjugated]

Human VE-Cadherin Quantikine ELISA Kit

Mouse VE-Cadherin ELISA Kit (Colorimetric)

VE-Cadherin Antibody (BV13) - BSA Free

Recombinant Human VE-Cadherin Fc Chimera His-tag Protein, CF